Company intelligence / Profile preview

Biosergen

Ownership: Private
Development stage: Phase 1

Overview

Lead candidate BSG005 has completed a Phase 1 trial in healthy volunteers with no significant side effects and demonstrated superior potency and safety compared to current treatments. Ongoing proof-of-concept studies show promising results with successful patient recovery from invasive fungal disease[1].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (specifically, polyene macrolide antifungals)
Industry: Biotech

Drug pipeline

2 assets

BSG005

1 more asset in the full pipeline.

Partnerships

Alkem Laboratories Limited (India): Commercial rights partnership for India and global collaboration on research and commercialization of BSG005

Beyond the preview

Go deeper on Biosergen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biosergen.